Self-trapped states and the related luminescence in PbCl2_2 crystals

We have comprehensively investigated localized states of photoinduced electron-hole pairs with electron-spin-resonance technique and photoluminescence (PL) in a wide temperature range of 5-200 K. At low temperatures below 70 K, holes localize on Pb$^{2+}$ ions and form self-trapping hole centers of Pb$^{3+}$. The holes transfer to other trapping centers above 70 K. On the other hand, electrons localize on two Pb$^{2+}$ ions at higher than 50 K and form self-trapping electron centers of Pb$_2$$^{3+}$. From the thermal stability of the localized states and PL, we clarify that blue-green PL band at 2.50 eV is closely related to the self-trapped holes.Comment: 8 pages (10 figures), ReVTEX; removal of one figure, Fig. 3 in the version

DEFECTS IN PbFCl

La conductivité ionique de monocristaux de PbFCl pur et dopé a été mesurée. La conductivité perpendiculaire à l'axe c est supérieure à la conductivité parallèle à cet axe d'environ trois puissances de 10 à la température ordinaire. Les nombres de transport ont été déterminés entre 510 et 550 K. Les expériences montrent que tPb est inférieur à 0,03, ce qui signifie que tF + tCl = 1. La conductivité de PbFCl a été comparée a la conductivité de PbC12 (défauts de Schottky) et de β-PbF2 (défauts anioniques de Frenkel). Cette comparaison, la conductivité des cristaux dopés et des considérations de structure sont en faveur d'un désordre thermique de Schottky.The ionic conductivity of undoped and doped PbFCl single crystals has been measured. The conductivity of PbFCl ⊥ c-axis exceeds at room temperature the conductivity || c-axis by about three powers of ten. Transference numbers have been deterrnined in the temperature region 510-550 K. The experiments revealed that tPb is less than 0.03, which means that tF + tCl = 1. The conductivity of PbFCl has been compared to the conductivity of PbCl2 (Schottky defects), and , β-PbF2 (anion Frenkel defects). This comparison, the conductivity of the doped crystals and structural considerations favour a thermal disorder of the Schottky-type

The penetrance of paraganglioma and pheochromocytoma in SDHB germline mutation carriers

Germline mutations in succinate dehydrogenase B (SDHB) predispose to hereditary paraganglioma (PGL) syndrome type 4. The risk of developing PGL or pheochromocytoma (PHEO) in SDHB mutation carriers is subject of recent debate. In the present nationwide cohort study of SDHB mutation carriers identified by the clinical genetics centers of the Netherlands, we have calculated the penetrance of SDHB associated tumors using a novel maximum likelihood estimator. This estimator addresses ascertainment bias and missing data on pedigree size and structure. A total of 195 SDHB mutation carriers were included, carrying 27 different SDHB mutations. The 2 most prevalent SDHB mutations were Dutch founder mutations: a deletion in exon 3 (31% of mutation carriers) and the c.423+1G>A mutation (24% of mutation carriers). One hundred and twelve carriers (57%) displayed no physical, radiological or biochemical evidence of PGL or PHEO. Fifty-four patients had a head and neck PGL (28%), 4 patients had a PHEO (2%), 26 patients an extra-adrenal PGL (13%). The overall penetrance of SDHB mutations is estimated to be 21% at age 50 and 42% at age 70 when adequately corrected for ascertainment. These estimates are lower than previously reported penetrance estimates of SDHB-linked cohorts. Similar disease risks are found for different SDHB germline mutations as well as for male and female SDHB mutation carrier

The phenotype of SDHB germline mutation carriers: A nationwide study

Objective: Succinate dehydrogenase B subunit (SDHB) gene germline mutations predispose to pheochromocytomas, sympathetic paragangliomas, head and neck paragangliomas and non-paraganglionic tumors (e.g. renal cell carcinoma, gastrointestinal stromal tumor and pituitary neoplasia). The aim of this study was to determine phenotypical characteristics of a large Dutch cohort of SDHB germline mutation carriers and assess differences in clinical phenotypes related to specific SDHB mutations. Design: Retrospective descriptive study. Methods: Retrospective descriptive study in seven academic centers. Results: We included 194 SDHB mutation carriers consisting 65 (33.5%) index patients and 129 (66.5%) relatives. Mean age was 44.8 +/- 16.0 years. Median duration of follow-up was 2.6 years (range: 0-36). Sixty persons (30.9%) carried the exon 3 deletion and 46 (23.7%) the c. 423 + 1G > A mutation. Fifty-four mutation carriers (27.8%) had one or multiple head and neck paragangliomas, 4 (2.1%) had a pheochromocytoma and 26 (13.4%) had one or more sympathetic paragangliomas. Fifteen patients (7.7%) developed metastatic paraganglioma and 17 (8.8%) developed non-paraganglionic tumors. At study close, there were 111 (57.2%) unaffected mutation carriers. Statistical analyses showed no significant differences in the number and location of head and neck paragangliomas, sympathetic paragangliomas or pheochromocytomas, nor in the occurrence of metastatic disease or other tumors between carriers of the two founder SDHB mutations (exon 3 deletion vs c. 423 + 1G > A). Conclusions: In this nationwide study of disease-affected and unaffected SDHB mutation carriers, we observed a lower rate of metastatic disease and a relatively high number of head and neck paragangliomas compared with previously reported referral-based cohorts

Increased mortality in SDHB but not in SDHD pathogenic variant carriers

Germline mutations in succinate dehydrogenase subunit B and D (SDHB and SDHD) are predisposed to hereditary paraganglioma (PGL) and pheochromocytoma (PHEO). The phenotype of pathogenic variants varies according to the causative gene. In this retrospective study, we estimate the mortality of a nationwide cohort of SDHB variant carriers and that of a large cohort of SDHD variant carriers and compare it to the mortality of a matched cohort of the general Dutch population. A total of 192 SDHB variant carriers and 232 SDHD variant carriers were included in this study. The Standard Mortality Ratio (SMR) for SDHB mutation carriers was 1.89, increasing to 2.88 in carriers affected by PGL. For SDHD variant carriers the SMR was 0.93 and 1.06 in affected carriers. Compared to the general population, mortality seems to be increased in SDHB variant carriers, especially in those affected by PGL. In SDHD variant carriers, the mortality is comparable to that of the general Dutch population, even if they are affected by PGL. This insight emphasizes the significance of DNA-testing in all PGL and PHEO patients, since different clinical risks may warrant gene-specific management strategies